Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Primary Breast Cancer ER+ve × enzalutamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 155 Neoplasm Metastasis 18 Breast Neoplasms 18 Prostatic Neoplasms, Castration-Resistant 16 Neoplasms 14 Prostate Cancer Metastatic 7 Metastatic Castration-Resistant Prostate Cancer 7 Metastatic Castration Resistant Prostate Cancer 7 Triple Negative Breast Neoplasms 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Pancreatic Neoplasms 4 Metastatic Castration-resistant Prostate Cancer 4 Melanoma 4 Carcinoma, Non-Small-Cell Lung 4 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Prostate Adenocarcinoma 3 Colorectal Neoplasms 3 Castration-resistant Prostate Cancer 3 Carcinoma, Hepatocellular 3 Bulbo-Spinal Atrophy, X-Linked 3 Adenocarcinoma 3 mCRPC 2 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Recurrence 2 Ovarian Neoplasms 2 Metastatic Hormone Sensitive Prostate Cancer 2 Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2 Lymphoma, Non-Hodgkin 2

Interventions

exemestane 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02676986 2024-07-05

ARB

Queen Mary University of London

Phase 2 Completed

Primary Breast Cancer ER+ve

Data powered by HemOnc (CC BY 4.0) Colophon ⚡